FATE
Fate Therapeutics, Inc.
There isn't enough reported data to score FATE yet.
FATE Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Unavailable |
FATE's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
FATE PE Valuation
FATE has no meaningful PE right now: it lost money over the past year.
FATE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect FATE's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
FATE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.03 | +$0.29 |
| Q2 2026 | -$1.05 | +$0.40 |
| Q1 2026 | -$1.09 | +$0.40 |
| Q4 2025 | -$1.15 | +$0.49 |
| Q3 2025 | -$1.32 | +$0.33 |
| Q2 2025 | -$1.45 | +$0.26 |
| Q1 2025 | -$1.49 | +$0.43 |
| Q4 2024 | -$1.64 | $0.00 |
FATE is still losing money, but far less than before: $1.03 per share over the past year, against $3.06 at its worst in late 2022.
FATE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.1M | +9.2% |
| Q1 2026 | $1.3M | -20% |
| Q4 2025 | $1.4M | -26% |
| Q3 2025 | $1.7M | -43% |
| Q2 2025 | $1.9M | -72% |
| Q1 2025 | $1.6M | -15% |
| Q4 2024 | $1.9M | +11% |
| Q3 2024 | $3.1M | +58% |
FATE's revenue has slid since its 2023 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1495% | +443 points |
| Q1 2026 | -2540% | -6.3 points |
| Q4 2025 | -2536% | +784 points |
| Q3 2025 | -1995% | -291 points |
| Q2 2025 | -1939% | -1273 points |
| Q1 2025 | -2534% | +119 points |
| Q4 2024 | -3320% | -451 points |
| Q3 2024 | -1704% | +934 points |
FATE's operating margin was −1495% last quarter, up 443 points from the same quarter a year ago.
FATE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$27.8M | -$1.2M |
| Q2 2026 | -$23.5M | +$2.5M |
| Q1 2026 | -$31.1M | +$3.9M |
| Q4 2025 | -$24.5M | +$3.4M |
| Q3 2025 | -$26.6M | +$3.3M |
| Q2 2025 | -$25.9M | +$6.4M |
| Q1 2025 | -$35M | -$1.6M |
| Q4 2024 | -$27.9M | +$8.9M |
FATE has burned cash in almost every quarter: −$107M over the past year, against −$115M the year before.
FATE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +3.3M shares |
| 1 year | +3.9% | +4.7M shares |
| 3 years | +25% | +25.1M shares |
| 5 years | +30% | +28.2M shares |
| Available history | +81% | +55.5M shares |
FATE has 124M diluted shares, up 3.9% from a year ago.
FATE Net Leverage
FATE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
FATE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 14.1 | Oversold |
FATE's weekly RSI is 38 (neutral) and its Stochastic is 14 (oversold).
FATE PE vs Healthcare Sector
FATE has no meaningful PE right now: it lost money over the past year.
FATE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.00 | 33% below |
| 20 week MA | $2.36 | 43% below |
| 50 week MA | $1.83 | 27% below |
| 100 week MA | $1.51 | 11% below |
| 200 week MA | $2.88 | 53% below |
FATE is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
FATE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.7 | $99.5 | +404% |
| 2021 | $99.5 | $64.3 | -35% |
| 2022 | $64.3 | $11.0 | -83% |
| 2023 | $11.0 | $3.74 | -66% |
| 2024 | $3.74 | $1.61 | -57% |
| 2025 | $1.61 | $1.00 | -38% |
| 2026 YTD | $1.00 | $1.34 | +34% |
FATE has finished five years in a row lower, and it's up 34% so far in 2026.